SCHEMBL26906853

SCHEMBL26906853

COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(C)cc1Nc1ncc(Cl)c(Nc2cc(Cl)ccc2NS(C)(=O)=O)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 15/20 0.71
▸ INSR P06213 6/20 0.69
▸ IGF1R P08069 6/20 0.69
▸ ALK Q9UM73 6/20 0.69
▸ MET P08581 2/20 0.58
▸ BMPR1B O00238 1/20 0.57
▸ PLK4 O00444 1/20 0.57
▸ STK25 O00506 1/20 0.57
▸ RIOK3 O14730 1/20 0.57
▸ CHEK1 O14757 1/20 0.57
▸ CASK O14936 1/20 0.57
▸ AURKA O14965 1/20 0.57
▸ GAK O14976 1/20 0.57
▸ DCLK1 O15075 1/20 0.57
▸ MUSK O15146 1/20 0.57
▸ EPHB6 O15197 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ MAP3K13 O43283 1/20 0.57
▸ DAPK3 O43293 1/20 0.57
▸ MAP3K7 O43318 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26906804 0.94 EGFR (0.73) EGFRINSRIGF1RALKMET
SCHEMBL26906668 0.94 EGFR (0.70) EGFRINSRIGF1RALKMET
SCHEMBL26906516 0.93 EGFR (0.80) EGFRINSRIGF1RALKMET
SCHEMBL26906654 0.93 ALK (0.70) EGFRINSRIGF1RALKMET
SCHEMBL26906536 0.93 EGFR (0.64) EGFRINSRIGF1RALKMET
SCHEMBL26906983 0.92 EGFR (0.68) EGFRINSRIGF1RALKMET
SCHEMBL26906638 0.92 EGFR (0.69) EGFRINSRIGF1RALKMET
SCHEMBL30692638 0.92 EGFR (0.69) EGFRINSRIGF1RALKMET
SCHEMBL26907018 0.91 EGFR (0.67) EGFRINSRIGF1RALKMET
SCHEMBL26906625 0.91 EGFR (0.67) EGFRINSRIGF1RALKMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP claimed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 EGFR 1/4885INSR 607/4885IGF1R 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback